FINAL REVIEW MEETING of NAMDIATREAM - Reims, 27th June 2014 PDF Print E-mail

The "Université de Reims Champagne Ardenne" (URCA) kindly hosted the official FINAL REVIEW MEETING of NAMDIATREAM (Reims, 27th June 2014)

The activities performed and the results achieved by NAMDIATREAM consortium in these 4 years of exciting collaboration have been presented to EC representatives. The meeting has been a unique opportunity to discuss how to exploit and translate into clinical practice the outstanding scientific results obtained and how to continue the exciting collaborations between the Academic, Research and Industrial Partners actively involved during NAMDIATREAM implementation.

Date: June 27th, 2014

Location: "Université de Reims Champagne Ardenne" (URCA), Faculty of Pharmacy of Reims, 51 rue Cognacq Jay, 51100 Reims (FRANCE)



NAMDIATREAM project aims to contribute to the fight against cancer which represents a major burden on the European population in terms of morbidity and mortality, with an estimated 3.2 million new cases and 1.7 million deaths per year. (source: European Commission Public Health Portal).

Namdiatream is a truly interdisciplinary and Pan-european consortium that builds around 7 High-Tech SMEs, 2 Multinational industries and 13 academic institutions. NAMDIATREAM will develop nanotechnology-based toolkit to enable early detection and imaging of molecular biomarkers of the most common cancer types and of cancer metastases, as well as permitting the identification of cells indicative of early-stage disease onset. The project is built on the innovative technology concepts of super-sensitive “lab-on-a-bead”, “lab-on-a-chip” and “lab-on-a-wire” nano-devices.

NAMDIATREAM will deliver photo-luminescent nano-particle-based reagents and diagnostic chips for high throughput early diagnosis of cancer and treatment. They allow identification of true “molecular signatures” of specific biomarkers and cancer cells within diagnostic material. The validation of these nano-tools will be carried out in compliance with the OECD-regulatory policies in nano-materials.

The evaluation of disease progression during surgical procedures, evaluation of tumour heterogeneity for optimised selective irradiation strategies and miniaturised point-of-care biomarker diagnostic devices adapted for micro-litre sample volumes thereby minimising the invasiveness and costs of diagnostic procedures.

Click on the image to zoom

The ETP Nanomedicine documents point out that nanotechnology has yet to deliver practical solutions for the patients and clinicians in their struggle against common, socially and economically important diseases such as cancer. Therefore NAMDIATREAM results will firstly aim to deliver to the diagnostic and medical imaging device companies involved in the consortium, and the clinical and academic partners. This could further provide the basis for cancer therapeutics as it will be possible to accurately assess the kinetics of cancer cell destruction during the course of appropriate therapy.

The European dimension of the NAMDIATREAM Consortium is ensured by the involvement of 22 partners with complementary profiles and skills, from 8 European Countries (Ireland, Spain, Austria, Germany, France, Italy, Belgium, UK) and 1 associated country (Switzerland).

NAMDIATREAM is co-funded by the European Community's under the FP7-Cooperation Programme.

NAMDIATREAM Principal coordinator: Prof Yuri Volkov (Trinity College Dublin, Ireland)

If you have any question regarding NAMDIATREAM please contact us, info (at) namdiatream (dot) eu